IQVIA Holdings Inc. (NYSE:IQV) Receives $249.05 Consensus Target Price from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus recommendation of “Moderate Buy” from the twenty-one ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $249.05.

A number of equities research analysts recently issued reports on the company. Truist Financial reissued a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th.

IQVIA Price Performance

NYSE:IQV opened at $185.85 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s 50 day moving average price is $194.94 and its two-hundred day moving average price is $208.73. The firm has a market capitalization of $32.77 billion, a price-to-earnings ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA has a 12-month low of $179.28 and a 12-month high of $254.80.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

Institutional Trading of IQVIA

Large investors have recently made changes to their positions in the company. Assetmark Inc. boosted its stake in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $230,000. Huntington National Bank raised its holdings in IQVIA by 7.4% during the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after acquiring an additional 56 shares during the period. Empowered Funds LLC raised its holdings in IQVIA by 33.9% during the 3rd quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock valued at $814,000 after acquiring an additional 871 shares during the period. Finally, Natixis Advisors LLC raised its holdings in IQVIA by 26.9% during the 3rd quarter. Natixis Advisors LLC now owns 245,136 shares of the medical research company’s stock valued at $58,090,000 after acquiring an additional 51,970 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.